Ultragenyx Pharmaceutical Inc

18 de set. de 2026, 20:03 UTC

Ultragenyx Pharmaceutical Inc. gained ground today after FDA approval for FAYUVI, its first treatment for Sanfilippo syndrome type A, despite ongoing investigations.

17 de set. de 2026, 23:06 UTC

Ultragenyx Pharmaceutical Inc. gained FDA approval for Fayuvi, the first gene therapy for Sanfilippo syndrome type A, driving after-market trading higher.

16 de set. de 2026, 20:10 UTC

Ultragenyx Pharmaceutical Inc shares fell to a new 52-week low as investors reacted to an upcoming FDA decision on UX111, expected by September 19.

15 de set. de 2026, 20:03 UTC

Ultragenyx Pharmaceutical is under investigation amid ongoing concerns following disappointing Phase 3 study results, contributing to a decline in share value.

14 de set. de 2026, 20:03 UTC

Ultragenyx Pharmaceutical is under investigation, contributing to a decline in shares today, despite receiving FDA orphan designation for GNE myopathy treatment.

11 de set. de 2026, 20:09 UTC

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

10 de set. de 2026, 20:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher during Thursday's session, fluctuating between a low of -1.28% and a high of 1.96%. No specific news was identified.

9 de set. de 2026, 20:02 UTC

Ultragenyx Pharmaceutical shares are declining as an investigation is initiated following the failure of its Phase 3 Aspire study for apazunersen.

8 de set. de 2026, 20:04 UTC

Ultragenyx shares are lower after its Phase 3 Aspire trial for apazunersen failed to meet endpoints, prompting expense reductions and mixed analyst ratings.

4 de set. de 2026, 20:02 UTC

Ultragenyx Pharmaceutical shares are higher today amid analyst updates, including Goldman Sachs lowering its price target to $19 and Barclays to $32.

3 de set. de 2026, 20:03 UTC

Ultragenyx Pharmaceutical's stock is lower after its Phase 3 Aspire trial failed to meet primary endpoints, prompting analyst downgrades and expense reduction plans.

2 de set. de 2026, 23:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

1 de set. de 2026, 23:01 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market trading despite positive Phase 3 data for GENGLYCOS, reflecting investor caution on FDA approval.

31 de ago. de 2026, 21:02 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment remains cautious amid Fed rate hike concerns.

28 de ago. de 2026, 22:56 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, though they remain below their 20-day moving average after recent declines.

26 de ago. de 2026, 20:08 UTC

Ultragenyx Pharmaceutical granted 45,984 restricted stock units to new non-executive officers as part of its Employment Inducement Plan. Shares are trading roughly flat.

25 de ago. de 2026, 23:16 UTC

Ultragenyx Pharmaceutical granted nearly 46,000 restricted stock units to new hires, boosting shares in after-market trading amid ongoing strategic initiatives for rare diseases.

24 de ago. de 2026, 23:16 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reflecting a modest increase since Monday's close amid no specific news to explain the movement.

22 de ago. de 2026, 00:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours, with no specific news identified. The broader market has shown notable gains.

21 de ago. de 2026, 23:11 UTC

Ultragenyx Pharmaceutical shares moved higher in after-market trading, reflecting broader market gains despite the absence of specific company news.

20 de ago. de 2026, 23:46 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, showing modest gains since Thursday's close, despite no specific news identified.

19 de ago. de 2026, 23:51 UTC

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

18 de ago. de 2026, 23:26 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market hours. No specific news was identified to explain the price movement.

17 de ago. de 2026, 23:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, gaining traction despite broader market volatility from geopolitical tensions and rising crude oil prices.

15 de ago. de 2026, 00:06 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reaching a high of 2.96% following Friday's close amid broader economic concerns.

14 de ago. de 2026, 22:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, advancing significantly since Friday's close amid easing expectations for Federal Reserve interest rate hikes.

13 de ago. de 2026, 19:16 UTC

Ultragenyx Pharmaceutical Inc. is declining, reflecting broader biotech sector weakness and a noted correlation with LABU's significant downturn.

12 de ago. de 2026, 22:16 UTC

Ultragenyx Pharmaceutical shares are higher in after-market trading, reflecting positive price movement amid a stable monetary policy outlook and recent inflation data.

11 de ago. de 2026, 19:36 UTC

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10 de ago. de 2026, 19:16 UTC

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.